Sanofi SA (SNY)
47.98
+0.20
(+0.42%)
USD |
NASDAQ |
Nov 21, 16:00
47.98
0.00 (0.00%)
After-Hours: 20:00
Sanofi Net Income (Quarterly): 3.096B for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.096B |
| June 30, 2024 | 1.198B |
| March 31, 2024 | 1.231B |
| December 31, 2023 | -597.68M |
| September 30, 2023 | 2.749B |
| June 30, 2023 | 1.565B |
| March 31, 2023 | 2.143B |
| December 31, 2022 | 3.181B |
| September 30, 2022 | 2.091B |
| June 30, 2022 | 1.252B |
| March 31, 2022 | 2.254B |
| December 31, 2021 | 1.314B |
| September 30, 2021 | 2.724B |
| June 30, 2021 | 1.444B |
| March 31, 2021 | 1.887B |
| June 30, 2020 | 8.368B |
| March 31, 2020 | 1.857B |
| December 31, 2019 | -68.65M |
| September 30, 2019 | 1.964B |
| June 30, 2019 | -97.74M |
| March 31, 2019 | 1.292B |
| December 31, 2018 | 289.80M |
| September 30, 2018 | 2.644B |
| June 30, 2018 | 909.85M |
| March 31, 2018 | 1.248B |
| Date | Value |
|---|---|
| December 31, 2017 | 130.71M |
| September 30, 2017 | 1.842B |
| June 30, 2017 | 1.141B |
| March 31, 2017 | 6.073B |
| December 31, 2016 | 852.26M |
| September 30, 2016 | 1.868B |
| June 30, 2016 | 1.308B |
| March 31, 2016 | 1.199B |
| December 31, 2015 | 365.44M |
| September 30, 2015 | 1.809B |
| June 30, 2015 | 1.439B |
| March 31, 2015 | 1.154B |
| December 31, 2014 | 1.672B |
| September 30, 2014 | 1.577B |
| June 30, 2014 | 1.066B |
| March 31, 2014 | 1.485B |
| December 31, 2013 | 1.443B |
| September 30, 2013 | 1.616B |
| June 30, 2013 | 585.15M |
| March 31, 2013 | 1.306B |
| December 31, 2012 | 502.01M |
| September 30, 2012 | 1.924B |
| June 30, 2012 | 1.480B |
| March 31, 2012 | 2.372B |
| December 31, 2011 | 1.875B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-597.68M
Minimum
Dec 2023
8.368B
Maximum
Jun 2020
2.094B
Average
1.872B
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 1.429B |
| GSK PLC | -75.47M |
| Eli Lilly and Co | 970.30M |
| Novavax Inc | -121.30M |
| Regeneron Pharmaceuticals Inc | 1.341B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 15.57B |
| Total Expenses (Quarterly) | 11.07B |
| EPS Diluted (Quarterly) | 1.237 |
| Enterprise Value | 136.14B |
| Gross Profit Margin (Quarterly) | 71.14% |
| Profit Margin (Quarterly) | 19.88% |
| Earnings Yield | 4.11% |
| Operating Earnings Yield | 9.56% |
| Normalized Earnings Yield | 6.677 |